GNPX

Genprex initiates site recruitment for Acclaim-2 clinical trial for its lung cancer drug REQORSA

Genprex presents positive preclinical data for lung cancer drug REQORSA at American Association for Cancer Research meeting

Genprex targets non-small cell lung cancer and diabetes via gene therapy

Genprex to present preclinical data for lung cancer drug REQORSA at American Association for Cancer Research meeting

Genprex announces $25 million registered direct offering priced at-the-market

Genprex, Inc. Announces $25 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules, Without Warrants

Genprex forms Clinical Advisory Board to support its oncology and diabetes development programs